Cosentyx is a medication used to treat various autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, which works by blocking a protein called interleukin-17A that is involved in the inflammatory response of these diseases [1].
According to a study published in Arthritis Research & Therapy, the long-term safety of Cosentyx was assessed in patients with psoriatic arthritis and ankylosing spondylitis over a period of 5 years. The study found that Cosentyx was generally well-tolerated and had a favorable safety profile, with no new safety signals identified over the course of the study. The most common adverse events reported were infections, which is a known risk associated with immunosuppressive medications [2].
However, the long-term effects of Cosentyx on organs have not been extensively studied. A review published on the National Center for Biotechnology Information (NCBI) website notes that while clinical trials have shown no evidence of increased risk of organ damage with Cosentyx, long-term studies are needed to fully evaluate the safety of the drug [3].
In summary, while there is no evidence of increased risk of organ damage with Cosentyx, long-term studies are needed to fully evaluate the safety of the drug. It is important for patients to discuss any concerns about the potential risks and benefits of Cosentyx with their healthcare provider before starting treatment [1][2][3].
Sources:
[1] DrugPatentWatch. Cosentyx. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] Mease, P. J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S., ... & Baraliakos, X. (2019). Five-year safety data from 5 clinical trials of subcutaneous secukinumab in patients with psoriatic arthritis. Arthritis research & therapy, 21(1), 1-10.
[3] National Center for Biotechnology Information. StatPearls [Internet]. StatPearls Publishing; 2021 Jan-. Chapter: Secukinumab. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK548346/